Document Detail


The impact of neo-osteogenesis on disease control in chronic rhinosinusitis after primary surgery.
MedLine Citation:
PMID:  23798364     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Osteitic bone is a feature of chronic rhinosinusitis (CRS), potentially playing a role in pathogenesis. Although seen after previous endoscopic sinus surgery (ESS), it is also a de novo feature in patients without prior interventions. In these patients, osteitis is associated with high tissue and serum eosinophilia. However, the impact of osteitis on prognosis is unclear. This study investigates the clinical and endoscopic outcomes between patients with and without osteitis after primary ESS.
METHODS: A prospective study of a cohort of previously unoperated patients with CRS undergoing ESS was performed. The sinuses were scored radiologically for osteitis using the Global Osteitis Score (GOS) and Kennedy Osteitis Score (KOS) preoperatively and were also scored dichotomously for the presence or absence of osteitis. Disease-specific quality of life (22-item Sino-Nasal Outcomes Test [SNOT-22]), nasal symptom score (NSS), endoscopic score (Lund-Kennedy), and clinical outcomes-including oral steroid use, frequency of nasal steroid irrigation, and infective exacerbations-were collected at baseline and 1 year postsurgery. The presence and extent of osteitis was assessed relative to clinical outcome.
RESULTS: Fifty-three patients were included (41.5% female, age 47.4 ± 13.8 years), 42.9% of which had radiologic osteitis. There was no significant association between the presence or severity of osteitis at the time of surgery and SNOT-22, NSS, or endoscopy scores at 12 months postsurgery. However, the presence of osteitis was associated with the need for a course of oral steroid postsurgery (odds ratio [OR]=4.17; p = 0.026). High tissue eosinophilia could not predict this alone (p = 0.55). There was no significant relationship between osteitis and the frequency of steroid irrigations or infective exacerbations.
CONCLUSION: Osteitis in CRS is associated with the degree of eosinophilia and as a independent process it was associated with the need for a course of systemic corticosteroid over a 12-month period, but did it not affect overall disease control.
Authors:
Peta-Lee Sacks; Kornkiat Snidvongs; Darren Rom; Peter Earls; Raymond Sacks; Richard J Harvey
Related Documents :
23798364 - The impact of neo-osteogenesis on disease control in chronic rhinosinusitis after prima...
15980744 - Endoscopic treatment of chronic pancreatitis.
11995494 - Pancreatic juice output and amylase level in the drainage fluid after pancreatoduodenec...
15615944 - The natural history of the incidentally discovered small simple pancreatic cyst: long-t...
15519184 - Reduced complement activation during cardiopulmonary bypass does not affect the postope...
23988554 - Applicability and mid-term results of endovascular treatment for descending thoracic ac...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-6-24
Journal Detail:
Title:  International forum of allergy & rhinology     Volume:  -     ISSN:  2042-6984     ISO Abbreviation:  Int Forum Allergy Rhinol     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-6-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101550261     Medline TA:  Int Forum Allergy Rhinol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2013 The Authors. International Forum of Allergy & Rhinology published by Wiley Periodicals, Inc., on behalf of ARS-AAOA, LLC.
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, University of NSW, Sydney, Australia; Department of Otolaryngology-Head and Neck Surgery, St. Vincent's Hospital, Sydney, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy and safety of rituximab given at 1000 mg on days 1 and 15 compared to the standard regimen ...
Next Document:  Sub-10 nm Graphene Nanoribbon Array Field-Effect Transistors Fabricated by Block Copolymer Lithograp...